Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Equity Average: 2021-2023

Historic Equity Average for Cullinan Therapeutics (CGEM) over the last 3 years, with Sep 2023 value amounting to $484.2 million.

  • Cullinan Therapeutics' Equity Average fell 18.67% to $484.2 million in Q3 2023 from the same period last year, while for Sep 2023 it was $484.2 million, marking a year-over-year decrease of 18.67%. This contributed to the annual value of $480.2 million for FY2022, which is 53.50% up from last year.
  • As of Q3 2023, Cullinan Therapeutics' Equity Average stood at $484.2 million, which was down 1.71% from $492.6 million recorded in Q2 2023.
  • In the past 5 years, Cullinan Therapeutics' Equity Average ranged from a high of $595.4 million in Q3 2022 and a low of $335.0 million during Q1 2021.
  • For the 3-year period, Cullinan Therapeutics' Equity Average averaged around $478.6 million, with its median value being $484.2 million (2023).
  • Its Equity Average has fluctuated over the past 5 years, first skyrocketed by 31.72% in 2022, then fell by 18.67% in 2023.
  • Quarterly analysis of 3 years shows Cullinan Therapeutics' Equity Average stood at $435.4 million in 2021, then climbed by 28.74% to $560.6 million in 2022, then declined by 18.67% to $484.2 million in 2023.
  • Its Equity Average was $484.2 million in Q3 2023, compared to $492.6 million in Q2 2023 and $510.3 million in Q1 2023.